Elevated C-reactive protein and failure to achieve remission in pediatric lupus nephritis: A retrospective cohort study

儿童狼疮性肾炎中C反应蛋白升高与未达到缓解的关系:一项回顾性队列研究

阅读:3

Abstract

Lupus nephritis (LN) is a serious complication that adversely affects the prognosis of children with systemic lupus erythematosus. However, short-term prognostic indicators for LN in this population remain unclear. This retrospective cohort study aimed to identify factors associated with treatment remission in Chinese children with LN, with a focus on inflammatory markers. We included 72 children aged 0 to 18 years diagnosed with LN at our center between January 2022 and December 2024. Partial remission was defined as a ≥50% reduction from baseline in proteinuria and to an absolute value of <3.0 g/g (300 mg/mmol), measured as the protein-to-creatinine ratio from a 24-hour urine collection, accompanied by stabilization or improvement in kidney function (estimated glomerular filtration rate, eGFR, within ±10% to 15% of baseline). The non-remission group comprised patients who failed to meet the above partial remission criteria within the 8 to 24 week follow-up period. Both univariate and multivariate Cox regression analyses revealed that elevated C-reactive protein (CRP) levels were significantly associated with failure to achieve remission (univariate hazard ratio 1.067, 95% CI: 1.011-1.126, P = .019; multivariate hazard ratio 1.075, 95% CI: 1.019-1.134, P = .008). A nomogram incorporating CRP demonstrated moderate discriminatory capacity for remission status at 24 weeks (AUC = 0.739). These findings indicate that baseline CRP is an independent risk factor for short-term remission failure in pediatric LN, suggesting that its monitoring may be beneficial for guiding clinical interventions. In conclusion, elevated CRP is an independent risk factor for short-term remission failure, and its monitoring may be beneficial for assessing treatment outcome.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。